title: Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red light.
abstract: We previously demonstrated that exposure to red light (550-670 nm) accelerates epidermal permeability barrier recovery after barrier disruption. Furthermore, we showed that photosensitive proteins, originally found in retina, are also expressed in epidermis. In retina, transducin and phosphodiesterase 6 play key roles in signal transmission. In this study, we evaluate the role of phosphodiesterese 6 in the acceleration by red light of epidermal permeability barrier recovery. Immunohistochemical study and reverse transcription-PCR assays confirmed the expression of both transducin and phosphodiesterase 6 in epidermal keratinocytes. Topical application of 3-isobutyl-1-methylxanthine, a non-specific phosphodiesterase inhibitor, blocked the acceleration of the barrier recovery by red light. Topical application of zaprinast, a specific inhibitor of phosphodiesterases 5 and 6, also blocked the acceleration, whereas T0156, a specific inhibitor of phosphodiesterase 5, had no effect. Red light exposure reduced the epidermal hyperplasia induced by barrier disruption under low humidity, and the effect was blocked by pretreatment with zaprinast. Our results indicate phosphodiesterase 6 is involved in the recovery-accelerating effect of red light on the disrupted epidermal permeability barrier.
authors.affiliation: Shiseido Innovative Science Research & Development Center, Yokohama, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Goto
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Ikeyama
authors.forename: Moe
authors.initials: M
authors.lastname: Tsutsumi
authors.forename: Sumiko
authors.initials: S
authors.lastname: Denda
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Denda
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000008:administration & dosage / Q000494:pharmacology; D000096:Acetone / Q000494:pharmacology; D000818:Animals; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6 / Q000235:genetics / Q000378:metabolism; D004817:Epidermis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects / Q000648:ultrastructure; D015870:Gene Expression / Q000235:genetics; D006965:Hyperplasia / Q000139:chemically induced / Q000517:prevention & control / Q000532:radiotherapy; D008297:Male; D051379:Mice; D008812:Mice, Hairless; D009287:Naphthyridines / Q000008:administration & dosage / Q000494:pharmacology; D010539:Permeability; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D010789:Phototherapy; D011688:Purinones / Q000008:administration & dosage / Q000494:pharmacology; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D012867:Skin / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000528:radiation effects / Q000648:ultrastructure; D015293:Transducin / Q000235:genetics / Q000378:metabolism; D014867:Water / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects* / Q000528:radiation effects*
chemical_list: D009287:Naphthyridines; D010726:Phosphodiesterase Inhibitors; D011688:Purinones; D011743:Pyrimidines; C473961:T0156; D014867:Water; D000096:Acetone; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6; D015293:Transducin; C011145:zaprinast; D015056:1-Methyl-3-isobutylxanthine